Answers are grounded in this paper and cite their sources.
Develops plasmonic nanozymes to disrupt redox homeostasis in tumors, suggesting improved cancer therapy effectiveness.
Tumor nanocatalytic therapy represents a promising transformative technology for treating malignant tumors, yet is often limited by insufficient catalytic activity and adaptive tumor microenvironment (TME) resistance. Herein, we develop a plasmonic Pt‐CuO 2 nanozyme that integrates plasmonic enhancement with self‐sufficient H 2 O 2 supply for augmented cascade catalytic therapy. The nanozyme comprises Pt nanoparticles (NPs) and CuO 2 nanodots co‐deposited on Au nanostars and encapsulated within PEGylated ZIF‐8 metal–organic frameworks (MOFs). It exhibits strong near‐infrared localized surface plasmon resonance, enables intrinsic H 2 O 2 generation, and depletes glutathione, effectively disrupting intratumoral redox homeostasis. Under acidic TME conditions, the MOFs degrade, releasing Pt NPs and CuO 2 nanodots to produce ∙OH via peroxidase‐like and Fenton‐like catalytic reactions. Plasmonic heating and “hot electron” injection under 808 nm laser irradiation further promote ∙OH generation. This process induces mitochondrial dysfunction, suppresses adenosine triphosphate biosynthesis and downregulates heat shock proteins, thereby increasing thermal sensitivity of cancer cells and enhancing the efficacy of mild plasmonic hyperthermia therapy (PHT). In a triple‐negative breast cancer murine model, the nanozyme demonstrates superior anticancer performance through the synergy of plasmon‐enhanced catalysis, self‐supplied H 2 O 2 , redox homeostasis disruption, and mild PHT. This study provides a novel strategy for efficient nanocatalytic therapy with substantial potential for clinical translation.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: